Clinical Trial for Asses the Safety and Efficacy of Vitamin C and Vitamin E in Combination Versus Placebo for Treating Cognitive and Behavior Disorder in Children With Fragile X Syndrome


The purpose of this study is to determine vitamin C and vitamin E in combination are effective in the treatment of cognitive and behavior disorder in children with fragile X syndrome.

Full Title of Study: “Clinical Trials Phase III, Double Blind, Crossover to Asses the Safety and Efficacy of Vitamin C and Vitamin E in Combination Versus Placebo for Treating Cognitive and Behavior Disorder in Children With Fragile X Syndrome”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: October 2017

Detailed Description

The combination of vitamin E and vitamin C supplementation has been associated with a lower prevalence (-78%) and incidence (-64%) of Alzheimer's disease in the elderly population. It has recently been shown that dietary vitamin E supplementation reduces the production of free radicals inhibiting NADPH oxidase activity in circulating neutrophils. Another work describes the inhibition of glutamate release by activated microglia in cell cultures incubated with vitamin E, effect that can prevent excitotoxicity.

The investigators propose to evaluate the effectiveness of treatment in neurodevelopmental disorders affected by fragile X syndrome (FXS) with lipophilic compounds antioxidants such as tocopherol and hydrophilic compounds antioxidants such as ascorbic acid, which regulate oxidative stress and improve learning and behavioral mouse model and humans.

Our group has positive results in the use of this combination of antioxidants as a treatment for fragile X syndrome in adolescents. This disease has developed previous clinical trials with EUDRACT codes: 2009-017837-23 and 2013-004276-35.

The use of the combination of vitamin C and E in the treatment of cognitive and behavioral disorder in FXS, is patented PCT-050 187 with reference number 2011070875

This combination will be administered as a single oral dose with a total dose of 10mg / kg / day for each of the vitamins. This dose is maintained within the therapeutic range of both antioxidants.


  • Drug: Vitamin C 10mg/Kg Vitamin E 10 mg/Kg
  • Drug: Placebo
    • Placebo

Arms, Groups and Cohorts

  • Experimental: Vitamin C 10 mg/Kg + Vitamin E 10 mg/Kg
    • Vitamin C and Vitamin E supplementation 10 mg/kg/ day
  • Placebo Comparator: Placebo
    • Placebo solution

Clinical Trial Outcome Measures

Primary Measures

  • Autism Treatment Evaluation Checklist (ATEC).
    • Time Frame: 32 weeks
  • Global Clinical Impression (GCI)
    • Time Frame: 32 weeks
  • Peabody Picture Vocabulary Test (PiVT)
    • Time Frame: 32 weeks
  • Battelle developmental inventory screening
    • Time Frame: 32 weeks
  • Vineland Adaptive Behavior Scales
    • Time Frame: 32 weeks
  • Adverse event reported
    • Time Frame: 32 weeks
  • Quantitative Checklist for Autism in Toddlers (Q-Chat) test
    • Time Frame: 32 weeks

Secondary Measures

  • Golberg scale GHQ-28
    • Time Frame: 32 weeks
  • Quality life SF36 test
    • Time Frame: 32 weeks
  • Psychological General Well-Being Index
    • Time Frame: 32 weeks
  • Sleep Disturbance Scale for Children
    • Time Frame: 32 weeks

Participating in This Clinical Trial

Inclusion Criteria

1. Diagnosis of Fragile X syndrome by genetic testing of molecular biology, full mutation result methylation.

2. Having an older age of 1 year and less than 9 years

3. Having signed the informed consent document before starting their participation in the trial.

Exclusion Criteria

1. Any advanced, severe or unstable disease.

2. Individuals with other psychiatric diagnosis as the first diagnosis.

3. It have been suffered serious medical problems in the last 12 months.

4. Be taking more than 100 mg of vitamin E or C a day in the last month.

5. Having physical, mental or sensory impairments that prevent the assessment of effectiveness.

6. Hypersensitivity to any component of the preparation.

7. Liver failure or severe renal or previous history of kidney stones.

8. Any treatment regimen, including treatment with psychotropic drugs and / or anticonvulsant therapy that has not been stable for a period ≥ 4 weeks before randomization.

9. Current treatment with more than two psychoactive medications, excluding medication used specifically for the control of seizures.

10. Hypoprothrombinemia secondary to vitamin K deficiency

11. Sensitivity to any of the compounds of formula treatment.

12. Patients diagnosed with congenital or idiopathic methemoglobinemia for diagnosis of glucose-6-phosphate dehydrogenase deficiency.

13. Use of oral anticoagulants, iron or vitamin A.

14. Forecast initiate or change pharmacological or no pharmacological interventions during the course of the study.

15. Patients weighing less than 4.2 kg

Gender Eligibility: All

Minimum Age: 1 Year

Maximum Age: 8 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
  • Collaborator
    • Delos Clinical
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Yolanda De Diego Otero, Ph D,


Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, Norton MC, Welsh-Bohmer KA, Breitner JC; Cache County Study Group. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol. 2004 Jan;61(1):82-8.

Castilla P, Dávalos A, Teruel JL, Cerrato F, Fernández-Lucas M, Merino JL, Sánchez-Martín CC, Ortuño J, Lasunción MA. Comparative effects of dietary supplementation with red grape juice and vitamin E on production of superoxide by circulating neutrophil NADPH oxidase in hemodialysis patients. Am J Clin Nutr. 2008 Apr;87(4):1053-61.

Barger SW, Goodwin ME, Porter MM, Beggs ML. Glutamate release from activated microglia requires the oxidative burst and lipid peroxidation. J Neurochem. 2007 Jun;101(5):1205-13. Epub 2007 Mar 30.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.